Source-grounded facts extracted from MYRIAD GENETICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MYRIAD GENETICS INC reported first quarter ended March 31, 2026 results: revenue 200.4 million, net income net loss of $34.1 million, EPS loss per share was $0.09 per share. Guidance reaffirmed.
“First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test.”
MYRIAD GENETICS INC incurred credit facility of $200 million term loan credit facility with OrbiMed Royalty & Credit Opportunities IV, LP at the greater of the one-month SOFR Rate and 2.50% plus 6.50% maturing July 31, 2030.
“On July 31, 2025 (the “Closing Date”), Myriad Genetics, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent (in such capacity, “Administrative Agent”) and as initial lender, consisting of a $200 million term loan credit facility with an initial term loan (the “Initial Loan”) in a maximum principal amount of $125 million, which amount was funded on the Closing Date, and delayed draw term loans (the “Delayed Draw Loans” and together with the Initial Loan, the “Loans”) at the election of the Company on or prior to June 30, 2027, in a maximum principal amount of $75 million (the “Credit Facility”).”
Samraat S. Raha was appointed as Director at MYRIAD GENETICS INC.
“the Board also appointed Mr. Raha to the Board to serve as a Class II director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders as of the Effective Date to fill the vacancy on the Board that will be created by Mr. Diaz’ resignation.”
Samraat S. Raha was appointed as President and Chief Executive Officer at MYRIAD GENETICS INC.
“the Board appointed Samraat S. Raha, the Company's Chief Operating Officer, to succeed Mr. Diaz as its President and Chief Executive Officer on the Effective Date.”
Paul J. Diaz departed as President and Chief Executive Officer at MYRIAD GENETICS INC.
“Paul J. Diaz, the Company’s President and Chief Executive Officer, announced on February 24, 2025 that he will step down from those positions, and resign from the Company’s Board of Directors (the “Board”), on April 30, 2025”
MYRIAD GENETICS INC reported first quarter ended March 31, 2024 results: revenue $202.2 million, net income $26 million, EPS $(0.29). Guidance reaffirmed.
“Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: • First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.